Literature DB >> 34110401

Expect the unexpected.

Didier Blaise1.   

Abstract

Entities:  

Keywords:  MARROW AND STEM CELL TRANSPLANTATION/organ specific toxicity: infectious; cytomegalovirus; retospective study

Mesh：

Year:  2021        PMID： 34110401      PMCID： PMC8351886          DOI： 10.1182/blood.2021011368

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  10 in total

1.  The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.

Authors:  R Crocchiolo; L Castagna; S Furst; R Devillier; B Sarina; S Bramanti; J El-Cheikh; A Granata; S Harbi; L Morabito; C Faucher; A Rimondo; D Girardi; B Mohty; B Calmels; C Carlo-Stella; C Chabannon; R Bouabdallah; A Santoro; N Vey; P J Weiller; D Blaise
Journal:  Bone Marrow Transplant       Date:  2016-03-21       Impact factor: 5.483

2.  Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Authors:  Anne Bergeron; Sylvie Chevret; Angela Granata; Patrice Chevallier; Laure Vincent; Anne Huynh; Reza Tabrizi; Hélène Labussiere-Wallet; Marc Bernard; Sylvain Chantepie; Jacques-Olivier Bay; Anne Thiebaut-Bertrand; Sylvain Thepot; Nathalie Contentin; Luc-Matthieu Fornecker; Natacha Maillard; Karine Risso; Ana Berceanu; Didier Blaise; Regis Peffault de La Tour; Jason W Chien; Valérie Coiteux; Gérard Socié
Journal:  JAMA       Date:  2017-08-08       Impact factor: 56.272

3.  Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Authors:  Javier Bolaños-Meade; Ran Reshef; Raphael Fraser; Mingwei Fei; Sunil Abhyankar; Zaid Al-Kadhimi; Amin M Alousi; Joseph H Antin; Sally Arai; Kate Bickett; Yi-Bin Chen; Lloyd E Damon; Yvonne A Efebera; Nancy L Geller; Sergio A Giralt; Parameswaran Hari; Shernan G Holtan; Mary M Horowitz; David A Jacobsohn; Richard J Jones; Jane L Liesveld; Brent R Logan; Margaret L MacMillan; Marco Mielcarek; Pierre Noel; Joseph Pidala; David L Porter; Iskra Pusic; Ronald Sobecks; Scott R Solomon; Daniel J Weisdorf; Juan Wu; Marcelo C Pasquini; John Koreth
Journal:  Lancet Haematol       Date:  2019-03       Impact factor: 18.959

4.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Authors:  Francisco M Marty; Per Ljungman; Roy F Chemaly; Johan Maertens; Sanjeet S Dadwal; Rafael F Duarte; Shariq Haider; Andrew J Ullmann; Yuta Katayama; Janice Brown; Kathleen M Mullane; Michael Boeckh; Emily A Blumberg; Hermann Einsele; David R Snydman; Yoshinobu Kanda; Mark J DiNubile; Valerie L Teal; Hong Wan; Yoshihiko Murata; Nicholas A Kartsonis; Randi Y Leavitt; Cyrus Badshah
Journal:  N Engl J Med       Date:  2017-12-06       Impact factor: 91.245

5.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

6.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.

Authors:  Pierre Teira; Minoo Battiwalla; Muthalagu Ramanathan; A John Barrett; Kwang Woo Ahn; Min Chen; Jaime S Green; Ayman Saad; Joseph H Antin; Bipin N Savani; Hillard M Lazarus; Matthew Seftel; Wael Saber; David Marks; Mahmoud Aljurf; Maxim Norkin; John R Wingard; Caroline A Lindemans; Michael Boeckh; Marcie L Riches; Jeffery J Auletta
Journal:  Blood       Date:  2016-02-16       Impact factor: 22.113

7.  Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.

Authors:  Scott R Goldsmith; Muhammad Bilal Abid; Jeffery J Auletta; Asad Bashey; Amer Beitinjaneh; Paul Castillo; Roy F Chemaly; Min Chen; Stefan Ciurea; Christopher E Dandoy; Miguel Ángel Díaz; Ephraim Fuchs; Siddhartha Ganguly; Christopher G Kanakry; Jennifer A Kanakry; Soyoung Kim; Krishna V Komanduri; Maxwell M Krem; Hillard M Lazarus; Hongtao Liu; Per Ljungman; Richard Masiarz; Carolyn Mulroney; Sunita Nathan; Taiga Nishihori; Kristin M Page; Miguel-Angel Perales; Randy Taplitz; Rizwan Romee; Marcie Riches
Journal:  Blood       Date:  2021-06-10       Impact factor: 25.476

Review 8.  Current Use of and Trends in Hematopoietic Cell Transplantation in the United States.

Authors:  Anita D'Souza; Caitrin Fretham; Stephanie J Lee; Mukta Arora; Janet Brunner; Saurabh Chhabra; Steven Devine; Mary Eapen; Mehdi Hamadani; Parameswaran Hari; Marcelo C Pasquini; Waleska Perez; Rachel A Phelan; Marcie L Riches; J Douglas Rizzo; Wael Saber; Bronwen E Shaw; Stephen R Spellman; Patricia Steinert; Daniel J Weisdorf; Mary M Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-11       Impact factor: 5.609

Review 9.  Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.

Authors:  Natalia S Nunes; Christopher G Kanakry
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

10.  The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus.

Authors:  Jakob R Passweg; Helen Baldomero; Christian Chabannon; Grzegorz W Basak; Selim Corbacioglu; Rafael Duarte; Harry Dolstra; Arjan C Lankester; Mohamad Mohty; Silvia Montoto; Régis Peffault de Latour; John A Snowden; Jan Styczynski; Ibrahim Yakoub-Agha; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2020-02-17       Impact factor: 5.483
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.